BIOCAN PUPPY LYOPHILISATE FOR SUSPENSION FOR INJECTION (VIRUS FEBRIS CONTAGIOSAE CANIS MIN. 10 ⁴ ̇ ² TC1D₅₀ MAX 10 ⁵ ̇ ⁰ TC1D₅₀ AND PARVOVIRUS ENTERIOTIOTIS CANIS INACT MIN. 10 ⁷ ̇ ⁰ )

Indications

• Pain management
• Post-surgical recovery
• Infections
• Chronic inflammatory diseases
• Neurological disorders

Dosage

Children: Paediatric dosing in dogs is also highly variable and should be determined by a veterinarian based on the specific medication and the puppy's age, weight, and overall health.

Adults: Dosage for adult dogs varies significantly based on the specific medication and condition being treated. It is essential to refer to a veterinary professional for accurate dosing.

Mechanism of action

The pharmacological actions in canines often depend on the specific medication being used. For instance, non-steroidal anti-inflammatory drugs (NSAIDs) used in dogs, such as carprofen, work by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thus reducing the formation of prostaglandins that mediate inflammation and pain. Antibiotics may exert their effects by inhibiting bacterial cell wall synthesis or protein synthesis, ultimately leading to bacterial cell death or growth inhibition.

Pharmacodynamics

The pharmacodynamics of drugs used in canines typically involve their interaction with biological systems to produce therapeutic effects. For analgesics, the primary effect is pain relief, while anti-inflammatories reduce swelling and inflammation. The efficacy of these medications can vary based on the individual dog's health status, age, and breed, necessitating careful monitoring and dose adjustments.

Pharmacokinetics

Pharmacokinetics in dogs can vary significantly based on the drug's formulation and the dog's metabolic rate. Generally, after administration, drugs are absorbed into the bloodstream, distributed to tissues, metabolized primarily in the liver, and excreted through the kidneys. Factors such as age, size, health conditions, and concurrent medications can influence these processes, impacting the drug's effectiveness and safety.

Pregnancy

Safety during pregnancy has not been established. Use should be avoided unless the potential benefits outweigh the risks.

Breast-feeding

Safety during breastfeeding has not been established. Caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct light. Keep out of reach of children.

Indications

• Viral infections
• Bacterial infections
• Parasitic infections
• Fungal infections
• Contagious diseases like influenza, chickenpox, and tuberculosis

Dosage

Children: Refer to paediatric dosing guidelines based on the specific infectious agent and clinical context.

Adults: Refer to specific treatment guidelines based on the infectious agent and clinical context.

Mechanism of action

The mechanism of action for contagiosae can vary widely depending on the specific pathogen and the host's immune response. Generally, infectious agents invade host cells, reproduce, and cause cellular damage, leading to symptoms of disease. The immune system responds by activating various pathways, including the innate and adaptive immune responses, to eliminate the pathogen.

Pharmacodynamics

Pharmacodynamics in the context of contagiosae involves understanding how the body responds to the infectious agent and the medications used for treatment. This includes the interaction between the drug and the pathogen, the immune response elicited by the infection, and the resultant effects on the host's physiology. Medications may work by inhibiting pathogen replication, enhancing immune responses, or alleviating symptoms.

Pharmacokinetics

Pharmacokinetics for treatments related to contagiosae includes absorption, distribution, metabolism, and excretion of the drugs used. Absorption may be affected by the route of administration, with some drugs administered orally, intravenously, or topically depending on the infection's location. Distribution involves the drug's reach to tissues and fluids where the pathogen resides. Metabolism typically occurs in the liver, and excretion may primarily happen through the kidneys. These factors influence the drug's efficacy and safety.

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether contagiosae is excreted in human milk. Caution should be exercised when administering to a nursing mother.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Indications

• Bacterial gastroenteritis
• Viral gastroenteritis
• Parasitic infections of the intestines
• Acute enteritis

Dosage

Children: Refer to specific pediatric guidelines based on the pathogen identified and clinical severity.

Adults: Refer to specific antimicrobial guidelines based on the pathogen identified and clinical severity.

Mechanism of action

Enteriotiotis, as a condition rather than a specific drug, does not have a defined mechanism of action. However, treatments may include antibiotics or antimicrobials that work by inhibiting bacterial cell wall synthesis, protein synthesis, or nucleic acid synthesis, ultimately leading to the death of the pathogen responsible for the inflammation.

Pharmacodynamics

Pharmacodynamics in the context of enteriotiotis involves the ability of antimicrobial agents to reduce the bacterial load in the gastrointestinal tract, alleviate symptoms, and restore normal gut flora. The effectiveness of these agents can be influenced by the specific pathogen, its susceptibility, and the host's immune response.

Pharmacokinetics

Pharmacokinetics will vary greatly depending on the specific treatment used for enteriotiotis. General principles include absorption in the gastrointestinal tract, distribution throughout the body, metabolism primarily in the liver, and excretion via the kidneys. Duration of action and half-life will depend on the pharmacological properties of the chosen antimicrobial agent.

Pregnancy

Safety during pregnancy has not been established. Use only if clearly needed.

Breast-feeding

Caution is advised; consult a healthcare provider before use.

Storage

Store at room temperature, away from light and moisture.

Indications

• Fever
• Mild to moderate pain
• Headache
• Muscle aches
• Arthritis

Dosage

Children: Refer to the BNF for Children for specific pediatric dosing recommendations.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Febris primarily acts by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), which are responsible for the conversion of arachidonic acid to prostaglandins. Prostaglandins are mediators of inflammation and fever. By reducing the levels of these compounds, febris leads to decreased hypothalamic set-point, thereby lowering body temperature.

Pharmacodynamics

The pharmacodynamic effects of febris include its analgesic, antipyretic, and anti-inflammatory properties. It effectively reduces fever in response to infection or inflammation by acting on the hypothalamus. It also provides pain relief by inhibiting prostaglandin synthesis, thus alleviating symptoms associated with various conditions such as headaches, muscle aches, and arthritis.

Pharmacokinetics

Febris is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 1-2 hours following oral administration. It is metabolized primarily in the liver, undergoing conjugation to form inactive metabolites. The elimination half-life varies between individuals but is generally around 2-4 hours. The drug is excreted primarily through the kidneys, with a small amount eliminated in feces.

Pregnancy

Use with caution, as safety during pregnancy has not been established.

Breast-feeding

Use with caution, as safety during breastfeeding has not been established.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Viral infections
• Prevention of viral infections
• Management of specific viral diseases

Dosage

Children: Refer to the BNF for Children or product literature for paediatric dosing information.

Adults: Refer to the specific BNF or product literature for adult dosing information.

Mechanism of action

Inact works by interfering with the viral replication cycle. It may inhibit viral enzymes essential for replication or block viral entry into host cells. This action helps to reduce the viral load within the body, allowing the immune system to effectively combat the infection.

Pharmacodynamics

The pharmacodynamics of Inact involves the inhibition of viral propagation and the modulation of immune responses. It enhances the activity of antiviral cytokines and stimulates the production of interferons, which play a crucial role in the body's defense against viral infections. The drug may also exhibit effects on the host's immune cells, increasing their ability to fight off infections.

Pharmacokinetics

Inact is generally absorbed rapidly following administration. Its bioavailability may vary depending on the route of administration. The drug is metabolized primarily in the liver, and its metabolites are excreted via the kidneys. The half-life of Inact can vary, influencing the dosing schedule. Factors such as age, liver function, and renal function can affect the pharmacokinetics of the drug.

Pregnancy

There is limited data on the safety of inact during pregnancy. Consult a healthcare provider before use.

Breast-feeding

Limited data available on the excretion of inact in breast milk. Caution is advised when administering to breastfeeding mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Fifth disease (erythema infectiosum)
• Aplastic crisis in patients with hemolytic anemia
• Parvovirus B19 infection in immunocompromised patients

Dosage

Children: There are no specific pharmacological treatments for parvovirus infections; management is supportive. In children, parvovirus B19 infection typically resolves on its own, and symptomatic treatment is

Adults: There are no specific pharmacological treatments for parvovirus infections; management is supportive. Adults with parvovirus B19 infection are generally advised to rest and manage symptoms such as fever and pain.

Mechanism of action

Parvovirus B19 infects erythroid progenitor cells in the bone marrow, leading to lysis of these cells and a subsequent decrease in red blood cell production. The virus attaches to its receptor, globoside (also known as P antigen), which is present on the surface of erythroid progenitor cells. This binding facilitates viral entry and replication, disrupting normal erythropoiesis.

Pharmacodynamics

Parvovirus B19's primary effect is on the hematopoietic system, particularly impacting the production of red blood cells. In immunocompetent individuals, infection typically results in mild symptoms and self-limiting disease. However, in individuals with compromised immune systems or underlying hematological conditions, the virus can lead to severe anemia and other complications due to its effect on erythroid progenitors.

Pharmacokinetics

Parvovirus does not follow traditional pharmacokinetic principles as it is a virus rather than a pharmaceutical agent. Its replication occurs intracellularly, and it is spread via respiratory droplets or blood. The incubation period ranges from 4 to 14 days, and viremia can persist for weeks. The immune response is crucial for clearing the virus, with specific antibodies developing within a few weeks of infection.

Adverse effects

• Fever
• Malaise
• Rash
• Joint pain
• Anemia
• Lethargy

Precautions

• Immunocompromised patients may experience more severe symptoms.
• Pregnant women should be cautious due to potential risks to the fetus.

Pregnancy

Parvovirus B19 infection during pregnancy can lead to serious complications, including fetal anemia and hydrops fetalis.

Breast-feeding

There is no evidence to suggest that parvovirus B19 is transmitted through breast milk.

Storage

Parvovirus is a virus and does not require storage in a conventional sense; however, specimens should be handled according to biosafety guidelines.

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.